Fundos mútuos aumentam participações em farmacêuticas e empresas de crédito não bancário em abril

Gestores de fundos indianos direcionaram novos investimentos para empresas farmacêuticas e instituições financeiras não bancárias durante o mês de abril. As movimentações visaram ações defensivas em meio a preocupações com os preços do petróleo e tensões no Oeste Asiático.

As empresas farmacêuticas atraíram atenção especial devido a oportunidades como a expiração da patente da semaglutida. Ações como Aurobindo Pharma, Sun Pharma, Torrent Pharma e Mankind Pharma figuraram entre as compras realizadas por fundos de ações.

Artigos relacionados

Split-scene illustration of BSE trading floor showing high-priced stocks' divergent FY26 performance: laggards crashing amid global tensions, gainers surging.
Imagem gerada por IA

High-priced BSE stocks diverge in FY26 performance

Reportado por IA Imagem gerada por IA

Among 68 high-priced stocks trading above Rs 5,000 on the BSE, FY26 has brought more declines than gains amid global uncertainty and geopolitical tensions. The top six laggards fell 25-40%, while top gainers surged 40-130%. Institutional holdings vary across these stocks.

India's small-cap stocks surged 17.1% in April, marking their best monthly performance in at least a decade. The Nifty Smallcap 250 index rebounded sharply after a steep sell-off in March. Local investors snapped up undervalued stocks with strong growth potential.

Reportado por IA

Retail investors put ₹38,440 crore into equity mutual funds last month, a modest decline from March levels. The dip occurred amid uncertainty over oil prices and lower SIP collections.

Several brokerages have identified 10 largecap stocks in India with significant upside potential despite rising oil prices from the US-Iran war. Crude oil has surpassed $125 per barrel, fueling inflation fears and market uncertainty. Stocks like HDFC Bank and Bharti Airtel top the lists from firms including Jefferies and Axis Direct.

Reportado por IA

Nine BSE smallcap companies delivered standout performances in the March 2026 quarter, with net profits surging over 50% year-on-year and share prices rising 50% to 170% in the past year. Four of these stocks became multibaggers, more than doubling investor returns. Data from ACE Equity highlights the momentum amid mixed results from 168 reporting firms.

Equity mutual fund inflows in India surged 56% to Rs 40,450 crore in March from Rs 25,977 crore in February, according to AMFI data. Flexi-cap funds led with a record Rs 10,054 crore, while nine categories overall saw positive inflows. Small-cap and mid-cap funds also posted strong gains amid market corrections.

Reportado por IA

Indian IT stocks experienced a brief rebound on Wednesday, halting a five-day losing streak. Analysts, however, caution that this uptick may not last, with persistent bearish sentiments in derivatives. The sector has been under pressure in February amid growing concerns over AI's impact on revenues.

sexta-feira, 10 de abril de 2026, 23:18h

Equity mutual fund inflows hit 8-month high in March

sábado, 21 de março de 2026, 04:01h

Six passive mutual funds open for subscription

quinta-feira, 19 de março de 2026, 02:24h

Indian markets rebound cautiously after sharp March sell-off

quarta-feira, 11 de março de 2026, 09:24h

Indian defence stocks rise amid geopolitical tensions

domingo, 08 de março de 2026, 21:20h

Middle East conflict fuels global market volatility and oil price surge

sexta-feira, 06 de março de 2026, 19:04h

InCred Equities identifies 11 stocks with potential upside of up to 40%

terça-feira, 03 de março de 2026, 15:24h

Indian stocks face ongoing pressure from Middle East tensions

terça-feira, 03 de março de 2026, 08:08h

Twelve equity mutual funds surpass Rs 1,000 NAV with up to 24% CAGR

sábado, 28 de fevereiro de 2026, 05:23h

Vanguard’s India portfolio surges 60% to Rs 69,100 crore

sábado, 28 de fevereiro de 2026, 05:08h

FIIs invest Rs 22,615 crore in Indian equities in February

 

 

 

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar